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Abstract
Objectives: The COVID-19 pandemic is due to SARS-CoV-2 coronavirus infections. It swept across the world in the spring of 2020, and so far it has 
caused a huge number of hospitalizations and deaths. In the present study, the authors investigated serum anti-SARS-CoV-2 antibody prevalence in 
the period of June 1–September 25, 2020, in 7561 subjects in Modena, Northern Italy. Material and Methods: The study population included 5454 work-
ers referred to testing by their companies, and 2107 residents in the Modena area who accessed testing through self-referral. Results: The authors 
found the overall seroprevalence to be 4.7% (95% confidence interval [CI] 4.2–5.2%), which was higher in women (5.4%, 95% CI: 4.5–6.2%) than in 
men (4.3%, 95% CI: 3.7–4.9%), and in the oldest age groups (7.3%, 95% CI: 5.2–9.3% for persons aged 60–69 years, and 11.8%, 95% CI: 8.6–15.1%, for 
persons aged ≥70 years). Among the occupational categories, the highest seroprevalence was found in healthcare workers (8.8%, 95% CI: 7.0–10.5%), 
dealers and vehicle repairers (5.2%, 95% CI: 2.9–7.6%), and workers in the sports sector (4.0%, 95% CI: 1.8–6.1%), while there was little or no such 
evidence for those employed in sectors such as transport and storage, accommodation and restaurant services, and the school system. Conclusions: 
These results have allowed, for the first time, to assess population seroprevalence in this area of Italy severely hit by the epidemic, while at the same time 
identifying the subgroups at a higher risk of exposure to SARS-CoV-2. Int J Occup Med Environ Health. 2022;35(1)
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INTRODUCTION
The severe acute respiratory syndrome due to corona-
virus 2 (SARS-CoV-2), named COVID-19, was declared 
a  pandemic by the  World Health Organization (WHO) 
on March 11, 2020. This is a  novel and extremely seri-
ous health condition. The  SARS-CoV-2 infection swept 
across the entire world: by December 2020, it had caused 
more than 79 million infection cases and 1.7 million re-
lated deaths according to WHO. Currently, there are no 
drug treatments that have proven fully effective [1], but 
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of the first wave of the epidemic, when the number of di-
agnostic tests performed was low [5].
For these reasons, assessing the  seroprevalence of anti-
SARS-CoV-2 antibodies could be very informative in 
light of the  expected large number of SARS-CoV-2 in-
fections being mainly undetected due to the absence or 
paucity of clinical symptoms. Seroprevalence estimates 
may also allow for identifying the population groups at 
the greatest risk of developing COVID-19, including age- 
and sex-specific groups, and occupational categories. 
A number of studies have assessed seroprevalence within 
specific communities all over the world, but this has gen-
erally involved small population samples and specific cat-
egories [15–17].
The purpose of the present study was to evaluate the prev-
alence of serum-specific antibodies against SARS-CoV-2 
in subjects living in the central-western part of the Emilia 
Romagna region. In particular, the authors aimed to ex-
plore the extent of asymptomatic or pauci-symptomatic 
infections by identifying the  percentage of previously 
infected individuals. The  second aim was to determine 
which characteristics of the study population could have 
favored the development of the SARS-CoV-2 infection.
MATERIAL AND METHODS
Study population
The authors carried out a cross-sectional study in a pop-
ulation of the  Emilia Romagna region, Northern Italy. 
Starting from April 2020, a few private laboratory facili-
ties were authorized by the Emilia Romagna local author-
ities to carry out serological tests pursuant to regional 
legislation (DGR350 of April 16, 2020 “COVID19: Disci-
pline of serological tests”). Among the first 8 laboratories 
to be accredited on the regional level was the Test Labora-
tory of Modena, a province located in the central-western 
part of the region (Decree PG/2020/0307727 of April 22, 
2020). Following the approval by the “Area Vasta Emilia 
Nord” Ethics Committee (No. 24690/20), the  authors 
the upcoming vaccines should guarantee population cov-
erage  [2] although only when herd immunity is estab-
lished [3].
In Italy, the  first nation to be severely hit by this infec-
tion, the epidemic was first recognized on February 21, 
2020 [4]. The first wave mainly affected Northern Italy [5], 
with a rapid rise in the number of cases and the peak on 
March 21, 2020 (657 cases), followed by a decline and sta-
bilization of cases below 600 in June and July 2020  [6]. 
The reduction in case numbers in Italy, as well as in other 
countries, was possible thanks to tight mobility restric-
tions (the lockdown) imposed by the government, com-
bined with testing and tracing measures implemented by 
public hygiene departments [4,7] and other infection con-
tainment measures such as the use of face masks and per-
sonal hygiene measures [8]. As for most European coun-
tries, Italy witnessed the second wave of the pandemic in 
autumn 2020, and it was still affected in early 2021 [6]. 
The  factors affecting the  uneven distribution across 
the  territory of many countries are partially unknown, 
although they are likely to encompass environmental fac-
tors [9–11] as well as genetic determinants [12].
The SARS-CoV-2 infection, either in symptomatic indi-
viduals or in those asymptomatic for COVID-19, is identi-
fied following diagnostic molecular RT-PCR tests based on 
swabs, recognizing the infection status through viral RNA 
detection. The implementation of these molecular tests at 
the population level has largely depended on public health 
policies, the availability of analytical facilities and reagents 
over space and time, the willingness of individuals to par-
ticipate and mandatory rules applying, among others, to 
those entering the country or admitted to some working 
environments  [13]. Therefore, molecular testing results 
cannot adequately reflect the  total number of infected 
individuals over time and in different areas, apart from 
small communities characterized by extensive testing 
such as the small Italian community of Vo’ in the Veneto 
region [14]. This is particularly true for the initial period 
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the  whole study population and in selected subgroups. 
In  data analysis and interpretation, they preferred to 
focus on the  strength and the  statistical precision of 
the point estimates, instead of relying on statistical signif-
icance testing and p-value cutpoints [18–20]. They pro-
vided 95% CI for the  distributions of anti-SARS-CoV-2 
antibody positive tests in the whole study population and 
its subgroups.
In particular, for occupational categories, the authors di-
vided the  participating workers into 12 wide categories 
according to 2007 Ateco (economic activity classifica-
tion, Ateco 2007 – ISTAT). For the purpose of the study, 
the  highest level of aggregation of Ateco activities (the 
“section” level) was considered. Activities involving 
mostly sedentary and office work (Ateco sections J, K, 
M, N) were merged into a single category. With regard to 
section R: “Artistic, sports, entertainment and fun activi-
ties,” of the 327 subjects only 1 (negative at the serologi-
cal test) belonged to the sub-category of “other activities 
connected with lotteries and betting” while the remain-
ing 326  people belonged to the  world of sport (i.e.,  to 
the  classes, categories and sub-categories marked as 
“sports club activities,” “sports bodies and organizations, 
promotion of sporting events,” “sports association”); 
henceforth, they are referred to as “workers in the sports 
sector.” Microsoft Excel v. 16 (Microsoft Office 2019) and 
Stata software v. 16.1 (2021 – Stata Corp., College Station, 
TX) were used for data collection and analysis.
RESULTS
In the  study period, 7752 individuals were admitted to 
the laboratory facility to be tested for the presence of anti-
bodies against SARS-CoV-2 (Figure 1). Of these, 596 sub-
jects took the  test more than once. In  such cases, only 
the most recent result was considered. A few records (191) 
were discarded due to an internal reporting error inher-
ent in the analytical system on September 4, 2020. Table 1 
reports the characteristics of the 7561 study participants: 
collected all analytical data available to the  Test Labo-
ratory following the  implementation of serological tests 
to detect serum SARS-CoV-2 antibodies in workers and 
private individuals admitted to the facility in June 1–Sep-
tember 25, 2020, most of whom residing in the Modena 
province. The  workers were referred by their compa-
nies, which strongly recommended that their employees 
be tested. The  remaining individuals were admitted to 
the  facility through self-referral, and were not asked to 
report the reasons for which they sought testing.
Laboratory analysis
The Test Laboratory determined the serum prevalence of 
SARS-CoV-2 antibody positivity in the study participants 
using either quantitative or qualitative tests. Depending 
on the  participants’ original request, both quantitative 
and qualitative tests could be carried out on these sam-
ples. After receiving written consent, the Laboratory drew 
5 ml of venous blood (for quantitative tests) or a drop of 
peripheral blood (for qualitative tests) from the study par-
ticipants. As far as the quantitative analysis was concerned, 
the Laboratory used 2 different sets of tests. The first was 
the ELISA anti-SARS-CoV-2 test kit for IgA and IgG from 
EUROIMMUN® (PerkinElmer, Inc., Waltham, MA, USA), 
with 100% sensitivity 10 days after the symptoms onset 
and 92.5% specificity. The second was the Elecsys® Anti-
SARS-CoV-2 test kit for IgG and IgM (Roche Diagnostics, 
Risch-Rotkreuz, Swiss), with 100%  sensitivity 14 days 
after the  symptoms onset and 99.8% specificity. Until 
August 16, 2020, IgA and IgG had been tested, while from 
August 17, 2020, IgG and IgM were tested. As for the qual-
itative analysis, the KHB® diagnostic kit for SARS-CoV-2 
IgM/IgG antibody Colloidal Gold was used, with 98.81% 
sensitivity and 98.02% specificity.
Data analysis
The authors computed the  absolute and relative (%) 
prevalence of serum antibodies against SARS-CoV-2 in 
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 – 7.8% (95% CI: 4.7–10.8%) for Reggio Emilia (23/296 po-
si tive subjects),
 – 18.9% (95% CI: 13.6–24.2%) for Parma (40/212 posi-
tive subjects),
 – 7.4% (95% CI: 0.0–18.0%) for Bologna (2/27 positive 
subjects).
Overall, women showed slightly higher seroprevalence 
rates than men (5.4%, 95% CI: 4.5–6.2% vs. 4.3%, 95% CI: 
3.7–4.9%). The participants’ age was higher in the sero-
positive subjects (48.3 years, 95% CI: 46.6–50.1) than 
in the negative ones (43.6 years, 95%CI: 43.3–43.9). The 
highest seroprevalence emerged in the 2 oldest age groups: 
those aged ≥70 years showed 11.8% (95% CI: 8.6–15.1%) 
of anti-SARS-CoV-2 antibody seroprevalence; and those 
aged 60–69 years 7.3% (95% CI: 5.3–9.3%) seropreva-
lence. The quantitative test was undergone by 5347 par-
ticipants, while the rapid qualitative test was performed 
on 2214 subjects. Seroprevalence was considerably great-
er in the first group (5.8%, 95% CI: 5.2–6.4%) compared 
with the second one (2.0%, 95% CI: 1.4–2.6%).
Considering the quantitative tests, the positivity rates for 
the immunoglobulin tested were:
 – 0.3% for IgM (95% CI: 0.04–0.6% with 5/1579 posi-
tives),
 – 5.1% for IgG (95% CI: 4.6–5.7% with 275/5347 posi-
tives)
 – 5.6% for IgA (95% CI: 4.8–6.4% with 212/3768 posi-
tives).
As regards the  qualitative test, the  positivity rates for 
the immunoglobulin tested were:
 – 0.9% for IgM (95% CI: 0.5–1.2% with 19/2214 posi-
tives),
 – 1.4% for IgG (95% CI: 0.9–1.8% with 30/2214 posi-
tives).
The number of participants referred by their compa-
nies amounted to 5454, while 2107 referred themselves 
to the  laboratory for other unreported reasons. For 
the self-referred subjects, no information about the oc-
4683 (61.9%) were men and 2878 (38.1%) women, with 
the  overall age (M±SD) 44±14 years. Division by prov-
ince of residence indicates that they were from:
 – Modena – 5634 (74.5%),
 – Reggio Emilia – 296 (3.9%),
 – Parma – 212 (2.8%),
 – Bologna – 27 (0.4%),
 – other provinces –1392 (18.4%).
A stratified analysis by sex showed a similar distribution 
of both age and the province of residence. The majority 
of the participants were workers, and the distribution by 
occupational sector showed that they represented mainly 
“manufacturing activities” (32.8%), “information and 
communication services/financial and insurance activi-
ties; etc.” (31.5%), and “health sector” (18.0%), this latter 
with a  higher number of female participants (31.9%) 
compared to male participants (11.5%).
The total number of positive participants, i.e., those with 
a  positive test for serum anti-SARS-CoV-2 antibodies, 
regardless of the type of the test performed and the de-
tected Ig, amounted to 354 (4.7%, 95% CI: 4.2–5.2%), 
while 7207 (95.3%) participants were negative (Table 2). 
The prevalence rates of positivity depending on the prov-
ince of residence were:





included in the study
701 excluded because 596 subjects
took the test more than once:
only the most recent was considered
191 records discarded due to
an internal reporting error inherent 
to the analytical system
Figure 1. Flow-chart with a selection of the participants of the serum 
anti-SARS-CoV-2 antibody prevalence study, June 1–September 25, 2020, 
Modena, Northern Italy
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sented in Table  3. The  group with the  greatest preva-
lence of seropositivity was that of healthcare workers 
(8.8%, 95% CI: 7.0–10.5% of the  entire category), fol-
lowed by dealers and vehicle repairers (5.2%, 95% CI: 
cupational status was made available. Of a total of 5454 
workers, it was not possible to retrieve the Ateco code 
for 12, and they were excluded from further analyses. 
The results for the 5442 remaining employees are pre-






(N = 4683,  
61.9%)
women
(N = 2878,  
38.1%)
Age [years] (M±SD) 44±14 43±14 45±15
<65 years [n (%)] 6932 (91.7) 4356 (93.0) 2576 (89.5)
≥65 years [n (%)] 629 (8.3) 327 (7.0) 302 (10.5)
Province of residence [n (%)]
Modena 5634 (74.5) 3491 (74.5) 2143 (74.5)
Reggio Emilia 296 (3.9) 136 (2.9) 160 (5.6)
Parma 212 (2.8) 98 (2.1) 114 (4.0)
Bologna 27 (0.4) 14 (0.3) 13 (0.4)
other/missing data 1392 (18.4) 944 (20.2) 448 (15.6)
Referral category [n (%)]
private 2107 (27.9) 957 (20.4) 1150 (40.0)
workers 5454 (72.1) 3726 (79.6) 1728 (60.0)
Occupational sector (workers only)a [n (%)]
agriculture, forestry and fishing (A) 3 (0.1) 3 (0.1) 0 (0.0)
manufacturing activities (C) 1788 (32.8) 1436 (38.5) 352 (20.3)
water supply; sewer networks, waste management and remediation activities (E) 85 (1.6) 65 (1.7) 20 (1.2)
constructions (F) 26 (0.5) 22 (0.6) 4 (0.2)
wholesale and retail trade; repair of motors vehicles and motorcycles (G) 362 (6.6) 240 (6.4) 122 (7.1)
transport and storage (H) 102 (1.9) 59 (1.6) 43 (2.5)
activities of the accommodation and restaurant services (I) 13 (0.2) 6 (0.2) 7 (0.4)
information and communication services; financial and insurance activities; professional 
scientific and technical activities; rental, travel agencies, business support services (J, K, M, N)
1720 (31.5) 1168 (31.3) 552 (31.9)
education (P) 26 (0.5) 9 (0.2) 17 (1.0)
health sector (Q) 982 (18.0) 430 (11.5) 552 (31.9)
workers in the sports sector (R) 327 (6.0) 275 (7.4) 52 (3.0)
other service activities (S) 8 (0.1) 6 (0.2) 2 (0.1)
missing 12 (0.2) 7 (0.2) 5 (0.3)
a The letters indicate Ateco classification occupational categories.
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DISCUSSION
The survey has shown that in this population severely 
hit by the  epidemic the  percentage of subjects who got 
infected was close to 5%. This approaches 6% when con-
sidering only the subjects undergoing the quantitative se-
rological tests, and it drops to 2% when considering only 
subjects taking the  qualitative (rapid) tests considered 
less reliable. These variations may be due to the different 
intrinsic characteristics of the tests, but also to the pre-
ferred use of quantitative serological tests in the case of 
suspected infections.
2.9–7.6%), and workers in the sports sector (4.0%, 95% 
CI: 1.8–6.1%). Very limited or no antibody seropreva-
lence emerged in sectors such as “constructions,” “trans-
port and storage,” “activities of the accommodation and 
restaurant services,” and “education.” In  the  category 
of “manufacturing activities,” the  authors also investi-
gated the seroprevalence of the subgroup of “production 
of meat products (including poultry meat)”: of a  total 
of 14 subjects belonging to this class, none was tested 
positive. A  graphic representation of these results can 
be seen in Figure 2.























<20 years 248 (3.3) 12 (4.8) 133 (2.8) 7 (5.3) 115 (4.0) 5 (4.4)
20–29 years 1229 (16.3) 46 (3.7) 841 (18.0) 32 (3.8) 388 (13.5) 14 (3.6)
30–39 years 1505 (19.9) 56 (3.7) 953 (20.4) 31 (3.3) 552 (19.2) 25 (4.6)
40–49 years 1915 (25.3) 70 (3.7) 1169 (25.0) 35 (3.0) 746 (25.9) 35 (4.7)
50–59 years 1641 (21.7) 78 (4.8) 1027 (21.9) 46 (4.5) 614 (21.3) 32 (5.2)
60–69 years 643 (8.6) 47 (7.3) 362 (7.7) 25 (6.9) 281 (9.8) 22 (7.8)
≥70 years 380 (5.0) 45 (11.8) 198 (4.2) 24 (12.1) 182 (6.3) 21 (11.6)
Test type
quantitative 5347 (70.7) 309 (5.8) 3199 (68.3) 171 (5.3) 2148 (74.6) 138 (6.4)
qualitative 2214 (29.3) 45 (2.0) 1484 (31.7) 29 (2.0) 730 (25.4) 16 (2.2)
Antibody/Ig tested
IgA 3768 212 (5.6) 2205 112 (5.1) 1563 100 (6.4)
IgG 7561 305 (4.0) 4683 169 (3.6) 2878 136 (4.7)
IgM 3793 24 (0.6) 2478 16 (0.6) 1315 8 (0.6)
Referral category
private 2107 (27.9) 140 (6.6) 957 (20.4) 67 (7.0) 1150 (40.0) 73 (6.3)
workers 5454 (72.1) 214 (3.9) 3726 (79.6) 133 (3.6) 1728 (60.0) 81 (4.7)
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tified higher seroprevalence, especially in other areas of 
the North severely affected by the pandemic [16,22,23].
The authors found a higher percentage of positive fema-
les than males, consistent with other studies. In females, 
however, mortality rates were lower than in males [17,24]. 
This may be linked to a  number of factors: first of all, 
a greater susceptibility to infections among females (de-
spite greater resistance); secondly, lower COVID-19 le-
thality in females compared to males; and thirdly, familial 
and social roles of women increasing their risk of con-
tracting the virus.
In addition, the  authors found a  steep increase in se-
roprevalence in older age groups, since people aged 
60–69 years and ≥70 years showed the highest prevalence 
Focusing only on IgG of the  few subjects who took 
the  quantitative serological tests, seroprevalence ac-
counted for 5.1%. The figure differs from the results ob-
tained through the Italian national seroprevalence SARS-
CoV-2 antibody survey carried out on May 25–July 15, 
2020, by the Ministry of Health and the National Institute 
of Statistics  [21]. The  survey based on quantitative tests 
found IgG positivity to be 2.5% in the whole country and 
2.8% in the Emilia Romagna region only. However, no es-
timate for the Modena province is available from the na-
tional survey. The representativeness and composition of 
the  investigated population were different in the 2 stud-
ies as was their timing, thus hampering any meaningful 
comparison. Other studies carried out in Italy have iden-
Table 3. Anti-SARS-CoV-2 antibody (Ab) status and percentage of antibody positivity by occupational category (Ateco code) in workers  






















Agriculture, forestry and fishing (A) 0/0 3 0/3 0.0 – –
Manufacturing activities (C) 36/1788 2.0 30/1436 2.1 6/352 1.7
Water supply; sewer networks, waste management and remediation 
activities (E)
2/85 2.4 2/65 3.1 0/20 0.0
Constructions (F) 0/26 0.0 0/22 0.0 0/4 0.0
Wholesale and retail trade; repair of motors vehicles and motorcycles (G) 19/362 5.2 13/240 5.4 6/122 4.9
Transport and storage (H) 1/102 1.0 0/59 0.0 1/43 2.3
Activities of the accommodation and restaurant services (I) 0/13 0.0 0/6 0.0 0/7 0.
Information and communication services; financial and insurance activities; 
professional scientific and technical activities; rental, travel agencies, 
business support services (J, K, M, N)
57/1720 3.3 40/1168 3.4 17/552 3.1
Education (P) 0/26 0.0 0/9 0.0 0/17 0.0
Health sector (Q) 86/982 8.8 37/430 8.6 49/552 8.9
Workers in the sports sector (R) 13/327 4.0 11/275 4.0 2/52 3.8
Other service activities (S) 0/8 0.0 0/6 0.0 0/2 0.0
a The letters indicate Ateco classification occupational categories.
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the most exposed to SARS-CoV-2, followed by dealers, ve-
hicle repairers and sportsmen. Similarly high seropreva-
lence of anti-SARS-CoV-2 antibodies in healthcare work-
ers had already been identified, particularly in the areas 
of Northern Italy heavily affected by the  pandemic 
[15,25,26], with a  corresponding value in the  national 
survey of 5.3% [21]. This clearly highlights the high infec-
tion risk experienced by this crucial sector and the impor-
tance of increasing their protection towards SARS-CoV-2 
contact. Unfortunately, there are limited data on occupa-
tional groups other than healthcare workers that may have 
undergone excess risks of SARS-CoV-2 infection.
In their study, the authors found, on the one hand, that 
workers heavily involved in direct contact with such 
subjects as clients, patients and sports opponents had 
a  higher seroprevalence of anti-SARS-CoV-2 antibodies. 
On the other hand, no excess seropositivity emerged for 
office workers with no contact with the public (as might 
be expected), for workers from the  manufacturing and 
construction sectors, and for employees in transportation 
and storage. This indicates that, so far, these sectors have 
enforced enough physical distancing to mitigate the risk of 
airborne disease transmission from COVID-19. Interest-
ingly, no increased risk was found for workers in the ed-
ucation sector. In  this case, however, the  result was not 
unexpected by virtue of the limited mobility and remote 
work of employees during the national lockdown.
Excess seroprevalence of anti-SARS-CoV-2 antibod-
ies emerged in the  occupational groups of workers in 
the sports sector, including categories such as sportsmen. 
This is an interesting finding that allows for assessing 
the potential risk of close contacts during contact sports, as 
well as a higher risk of airborne viral transmission arising 
in such circumstances [27]. Although these estimates were 
based on a very limited sample size, and notwithstanding 
little evidence available from the literature, these data sug-
gest the need to further investigate the safety of team and 
community sports practice during the current pandemic. 
(7.3% and 11.8%, respectively). The  importance of this 
finding should be evaluated in light of the fact that these 
age groups have been indicated as displaying the highest 
COVID-19 mortality by the  Italian National Institute of 
Health [6]. In  addition, the  excess seroprevalence found 
in these age groups may still be somehow underestimat-
ing the real figures, because the death toll was the high-
est in these 2 age categories in Modena, as everywhere 
else. The present age-specific findings are in contrast with 
those from the  only national seroprevalence survey car-
ried out so far, in which the  age group with the  highest 
percentage of seropositive individuals was reported to be 
that of 50–59 years [21]. This may be due to some differ-
ences in terms of the period in which the seroprevalence 
survey was carried out, with this study having been com-
pleted more recently. In turn, this raises a number of rel-
evant issues, from the continuous and increasing exposure 
to the virus in the late spring and summer, when the lock-
down was lifted and mobility restrictions eased, to other 
characteristics of the 2 surveys concerning the representa-
tiveness of the underlying resident population.
As far as the  occupational risk factors of the  infection 

































The letters indicate Ateco classification occupational categories as reported in Table 1.
Figure 2. Subjects with anti-SARS-CoV-2 antibody positive (Ab+) tests by 
occupational category, June 1–September 25, 2020, Modena, Northern Italy
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already presented signs and symptoms of COVID-19. For 
the  latter, they were also unable to assess differences in 
disease severity, a factor that may have affected the extent 
and duration of the  immune response against SARS-
CoV-2  [35]. However, since all subjects were recruited 
within 7 months from the  beginning of the  pandemic, 
antibodies to SARS-CoV-2 levels should not have been 
waned but remained detectable, as also confirmed by 
a recent Chinese study showing that they persisted for at 
least 9 months [35]. In addition, the sample size was not 
enough to carry out a stratified analysis for some occu-
pational groups with low numbers of employees, which 
affected in some subgroups the  statistical precision of 
the estimates.
This study also has some strengths. To the best of the au-
thors’ knowledge, this is the first available study provid-
ing seroprevalence data in the Northern Italy population 
mirroring SARS-CoV-2 infections during the first wave. 
The  size of the  overall study population was large, and 
many specific occupational activities were represented, 
also given the highly industrialized pattern of the popu-
lation of the study region. Finally, the detailed informa-
tion made available about the  occupational status of 
the  study participants provided some helpful insights 
about the workers who experienced a higher burden of 
the disease and, therefore, were at a higher risk of virus 
transmission in their occupational environment.
CONCLUSIONS
Overall, this study provided, for the first time, an assess-
ment of population seroprevalence in the Northern Italy 
population severely hit by the  epidemic, with a  higher 
value when quantitative serological tests were performed, 
but a lower percentage when considering the less reliable 
rapid tests. Finally, these findings suggest that occupa-
tional subgroups at a  higher risk of exposure to SARS-
CoV-2 were healthcare workers, dealers and vehicle re-
pairers, and workers in the sports sector.
Interestingly, the  subgroup of “production of meat prod-
ucts (including poultry meat)” did not show any positivity 
to the serological test, an interesting finding – despite its 
small sample size – given the recent occurrence of small 
outbreaks in slaughterhouses or similar facilities [28,29].
The seroprevalence found in the  study participants 
may have slightly underestimated the  real incidence of 
the SARS-CoV-2 infection in the period considered. In fact, 
it has been suggested that anti-SARS-CoV-2 antibody se-
roprevalence decreases over time, particularly in the case 
of asymptomatic infections  [30]. However, recent data 
have not supported such a  substantial decrease [31,32]. 
In addition, even assuming such a decrease, a few months 
should elapse from the infection to make it relevant, while 
the study population was tested close to the possible ante-
cedent infection.
An assessment of seroprevalence may also enable esti-
mating the COVID-19 infection fatality rate in the study 
area, moving beyond the case-fatality rate. In particular, 
the former estimate can be expected to be clearly lower 
than the latter, given the higher number of infected sub-
jects emerging from seroprevalence surveys compared 
with molecular testing detection [21,33]. However, con-
sidering the  large number of deaths from COVID-19 in 
the  Modena population, as well as in several Northern 
Italy provinces, during the  first wave of the  pandem-
ic [10,34], and the comparison with other airborne viral 
diseases, there appears to be no doubt about the  very 
high severity of COVID-19 in this community, particu-
larly in selected population subgroups. Finally, despite 
the  limited seroprevalence rate in the study population, 
the  recently published nationwide findings suggest that 
even a small amount of humoral immunity may hamper 
subsequent waves of the disease [33].
Some limitations of this study must be outlined. The au-
thors were unable to collect detailed information about 
the  relevant characteristics of SARS-CoV-2 infection, 
such as whether the participants were asymptomatic or 
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